Comparative Pharmacology
Head-to-head clinical analysis: RAUSERPIN versus SERPALAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAUSERPIN versus SERPALAN.
RAUSERPIN vs SERPALAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rauwolfia alkaloid (reserpine) depletes catecholamines (norepinephrine, dopamine, serotonin) from sympathetic nerve endings and brain by irreversibly binding to vesicular monoamine transporter (VMAT). This results in reduced sympathetic outflow, decreased heart rate, and vasodilation.
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin at the presynaptic terminal.
Initial: 0.1-0.25 mg orally once daily; increase gradually to 0.5-1 mg per day in 2 divided doses. Maximum: 3 mg/day.
100 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life: 4-8 hours; clinical context: requires multiple daily dosing to maintain therapeutic levels.
Terminal elimination half-life is 12-14 hours in adults with normal renal function; prolonged to 24-36 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 60 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (60-70% as unchanged drug and metabolites); biliary/fecal (15-20%)
Primarily renal elimination (60-70% unchanged drug), with 20-30% biliary/fecal excretion as metabolites; less than 10% excreted unchanged in feces.
Category C
Category C
Antihypertensive
Antihypertensive